nL-MAPK8-001

Phase 2Small molecule

Nn-Lorem Foundation

nL-MAPK8-001 is one of 6 small molecule programs targeting Neurodevelopment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurodevelopmentActive, not recruiting

NeurodevelopmentPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Neurodevelopment

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 2

1 2

Rapamune

PPrism Pharmaceuticals

Phase 2

1 3

BPN14770

Shionogi

Phase 2

1 4

nL-MAPK8-001

Nn-Lorem Foundation

Phase 2

1 5

Recombinant Human Erythropoietin

Amgen

Preclinical

1 6

Vit B12

SSitaram Bhartia Institute of Science and Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Active, not recruiting

Neurodevelopment

NCT07197294

Clinical

Trials by Indication[1]

Neurodevelopment1 trial

Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)

Active, not recruiting·Nn-Lorem Foundation·Phase 1/2·NCT07197294·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nL-MAPK8-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nL-MAPK8-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nL-MAPK8-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — n-Lorem Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Nn-Lorem Foundation

nL-MAPK8-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Neurodevelopment1 trial

References

Drug Info

Quick Facts

Related News